IBR900 cell therapy for relapsed/refractory B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a type of B-cell lymphoma that is CD20 positive (a protein on the cancer cells).
- Your lymphoma has come back or not responded to at least one standard treatment (including a CD20-targeted drug).
- You have at least one measurable tumor (a lymph node >1.5 cm or other lesion >1 cm).
- You are in generally good health (ECOG score 0-2) and expected to live at least 3 more months.
- You have not had a stem cell transplant from a donor, and your lymphoma has not spread to your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that came back or did not improve after other treatments. The therapy uses your own immune cells to fight the cancer, and the study aims to see if it is safe and effective.
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This study is testing a new cellular therapy using immune cells (called CD20/CD19 cells) for patients with a certain type of lymphoma that has not been cured by standard treatments. The cells are designed to find and destroy your lymphoma cells, potentially helping you achieve remission.
This trial tests a new cell therapy (called RJMty19) for people with B-cell lymphoma that has returned or not responded to standard treatments. The therapy aims to find and attack cancer cells.
This early trial tests a new type of cell therapy (called ARI0003) for aggressive B-cell lymphomas that have not responded to standard treatments or have relapsed. The therapy uses your own immune cells to fight the cancer, and it may offer a new option when other treatments have not worked well.
Hear when a new Relapsed/Refractory B-cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.